検索結果

iod required for regulatory approval, resulting in early approval and launch. CRAO, the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...

int research. Under this agreement, Alchemedicine will discover and optimize drug candidate for one target of interest in Senju Pharmaceutical. With a sense of mission to serve the eye health of peopl...